GAITHERSBURG, Md., April 18 /PRNewswire-FirstCall/ — MedImmune, Inc. (Nasdaq: MEDI) today announced the publication of preclinical study data demonstrating a role for high mobility group box protein-1 (HMGB1), a nuclear DNA-binding protein, in the pathology of systemic autoimmune diseases such as systemic lupus erythematosus (SLE or lupus) and rheumatoid arthritis. Data to be published in the May 2007 issue of Nature Immunology show that HMGB1 is an essential component of DNA-immune complexes that stimulate immune cells to produce potent inflammatory proteins. The data supplement earlier preclinical evidence that HMGB1 may be an important factor in the sequence of events that result in severe tissue damage following injury or during chronic inflammation. The data also suggest that a blocking antibody to HMGB1 may provide protection in chronic inflammatory diseases.

“MedImmune is committed to developing innovative treatments for inflammatory diseases, and among our key areas of focus are the disease pathology of lupus and the role of B cells in autoimmunity,” said Anthony J. Coyle, vice president, research and development, and head, inflammation and autoimmunity research. “These data, applicable to several programs within our pipeline, demonstrate a novel mechanism by which HMGB1 mediates B cell activation and may contribute to the pathogenesis of autoimmune disorders.”

HMGB1′s potential role in chronic inflammatory diseases is the focus of ongoing preclinical research conducted by MedImmune in collaboration with its partner, Critical Therapeutics, Inc. The Nature Immunology article, titled “Toll-like receptor 9-dependent activation by DNA containing immune complexes is mediated by HMGB1 and RAGE,” contains data showing that HMGB1 is a key component of DNA-immune complexes that stimulate activation of B cells and plasmacytoid dendritic cells (pDCs) via the toll-like receptor 9 pathway (TLR9). Both B cells and pDCs are associated with immune system disorders such as lupus. The data also suggest that HMGB1 DNA-immune complexes augment production of inflammatory proteins by interacting with the receptor for advanced glycation end products (RAGE).

About HMGB1

HMGB1, a pro-inflammatory protein secreted by different cell types, is part of the body’s response to trauma and infection. HMGB1 is expressed at high levels beginning 12 to 72 hours after an injury, which is about the time inflammation-associated tissue damage begins. Because of the timing and duration of expression of HMGB1, it may be an important factor in the sequence of events that result in severe tissue damage following injury or during chronic inflammation.

About Lupus

According to the Lupus Foundation of America, approximately 1.5 million Americans may suffer from some form of lupus, a chronic inflammatory disease that causes the body to attack its own tissues and organs, including the skin, joints, blood and kidneys. Treatments for lupus include anti-inflammatory drugs, antimalarials, corticosteroids and drugs approved for other purposes, such as immunosuppressive agents given to cancer patients undergoing chemotherapy or medicines developed to treat patients with arthritis. Lupus occurs about 10 times more frequently in adult females than adult males, and is two to three times more common among African Americans, Hispanics, Asians and Native Americans.

About MedImmune, Inc.

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company’s website at www.medimmune.com.

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties, in particular, related to the research and development of antibodies targeting HMGB1. Such statements reflect management’s current views and are based on certain assumptions about the success of this program. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in MedImmune’s filings with the SEC. MedImmune is developing HMGB1-related product candidates for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.

SOURCE MedImmune, Inc.

CONTACT: Media, Kate Barrett, +1-301-398-4320, or Investors, Beatrice Pierre, +1-301-398-4905, both of MedImmune, Inc.

GAITHERSBURG, Md., April 2 /PRNewswire-FirstCall/ — MedImmune, Inc. (Nasdaq: MEDI) today announced that it has promoted three senior leaders within its research and development (R&D) and medical organizations. The new executive appointments include Iksung Cho, vice president, biostatistics; Anthony J. Coyle, Ph.D., vice president, R&D, and head, inflammation and autoimmunity research; and Barbara White, M.D., vice president, clinical development, inflammatory disease.

“As MedImmune drives progress through its pipeline, the company relies on a growing number of senior leaders to contribute their expertise strategically,” said David M. Mott, chief executive officer and president. “Iksung’s statistical contributions have been critical in ensuring that we have solid Phase 3 pivotal data in support of our near-to-market infectious disease product candidates. Similarly, Anthony and Barbara have used their depth of experience and knowledge to advance important programs within our growing inflammatory disease portfolio.”

In his new role as vice president, biostatistics, Iksung Cho manages a team of nearly 20 statisticians who conduct activities such as clinical trial design and analysis for MedImmune’s research, development, clinical, regulatory and manufacturing organizations. He joined Aviron in 1997 as the primary statistician for the company’s influenza vaccine program. MedImmune completed the acquisition of Aviron in 2002. Previously, Mr. Cho had worked at Merck Research Laboratories within the vaccines development group. He holds masters of science degrees in mathematics and statistics from Virginia Polytechnic Institute & State University and has completed additional graduate-level coursework at Virginia Polytechnic & State University and Temple University. Mr. Cho is also the co-author of approximately 30 manuscripts or abstracts on vaccines and statistics.

As vice president, research and development, and head, inflammation and autoimmunity research, Anthony J. Coyle, Ph.D., oversees MedImmune’s preclinical research in disease areas such as asthma, lupus, rheumatoid arthritis and sepsis. Prior to joining MedImmune as a senior director in 2005, Dr. Coyle served as director, inflammation biology, at Millennium Pharmaceuticals in Cambridge, Massachusetts. In addition, he worked as a research scientist in the immunology department at the Glaxo Institute for Molecular Biology in Geneva, Switzerland. He also has more than six years of experience as a post-doctoral research assistant in immunology and pharmacology at Institut Pasteur in Paris and the National Jewish Center of Immunology in Denver. Dr. Coyle is a member of the American Thoracic Society and has published more than 120 scientific papers. He earned his bachelor of science and doctoral degrees in pharmacology from Kings College of the University of London.

Barbara White, M.D., now serves as vice president, clinical development, inflammatory disease. She joined MedImmune in January 2006 as senior director, and was appointed head of the inflammatory disease group in clinical development in November 2006. Prior to joining MedImmune, Dr. White was a director of medical affairs, inflammation therapeutic area, at Amgen where her activities included leading non-registration internal and external clinical research programs. Prior to 2003, Dr. White served as professor of medicine in the division of rheumatology, department of medicine, at the University of Maryland School of Medicine. She was formerly associate chief of staff of the research service at the Baltimore Veteran Administration (VA) Medical Center, one of the largest VA-based research programs in the country, where her research focused on immune-mediated mechanisms of lung fibrosis in scleroderma. Dr. White also previously served as co-director of the Johns Hopkins University and University of Maryland Scleroderma Center. She has been active in the American College of Rheumatology, serving as chair of the research committee and as a member of the board of directors, and has served as an ad hoc member of the FDA Arthritis Advisory Committee. She has served on the editorial boards of Arthritis & Rheumatism and Arthritis Care and Research and has been a reviewer for numerous journals and grant review panels. Dr. White received her medical degree from the University of Pennsylvania School of Medicine and is board certified in Internal Medicine, Rheumatology and Allergy/Clinical Immunology. She completed her postdoctoral studies in basic cellular immunology at the National Institutes of Health.

About MedImmune, Inc.

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious disease, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company’s website at http://www.medimmune.com.

SOURCE MedImmune, Inc.

CONTACT: Media, Kate Barrett, +1-301-398-4320, or Investors, Beatrice Pierre, +1-301-398-4905, both of MedImmune, Inc.

“MedImmune is committed to developing innovative new treatments for patients who suffer from debilitating inflammatory diseases,” said Barbara White, M.D., senior director, clinical development, inflammatory diseases. “It is exciting to expand our evaluation of MEDI-545 to patients with psoriasis. We are encouraged by the progress of MEDI-545 to date, and hope to further our understanding about the role of type 1 interferons in the pathology of immunological diseases like psoriasis and lupus.”

A growing body of preclinical data suggests that type-1 interferons are involved in a range of chronic inflammatory diseases. Elevated type-1 interferon mRNA levels have been found in preclinical models of psoriasis, and inhibition of type 1 interferon in these models has been shown to block the development of psoriasis. Preclinical study results have also demonstrated that interferon-alpha-induced genes and proteins are over-expressed in the skin in animal models of psoriasis.

Designed to evaluate safety and tolerability, MedImmune’s Phase 1 dose- escalation trial will be conducted at three sites in North America. Patients will be dosed once and subsequently evaluated for a period of 126 days, including blood and skin analysis at regular intervals.

MedImmune is advancing its anti-interferon-alpha program on several other fronts. The company’s ongoing Phase 1 study in lupus patients will be the subject of a poster presentation at the 8th International Lupus Consortium, to be held May 24-26 in Shanghai. The single-dose study was initiated by MedImmune in April 2006, based on preclinical research conducted in collaboration with its partner, Medarex, Inc. In addition to preclinical data suggesting that elevated levels of interferon alpha may be associated with lupus disease activity, preclinical study results also indicated that MEDI-545 may suppress the abnormal immune activity associated with lupus by binding to multiple interferon-alpha subtypes seen in the serum of lupus patients.

Additionally, MedImmune recently filed an application with the U.S. Food and Drug Administration (FDA) for MEDI-545 to be granted orphan drug status in a third indication, idiopathic inflammatory myositis. An area of unmet medical need, idiopathic inflammatory myositis is an immunological disease that involves chronic muscle inflammation, pain and weakness.

About Psoriasis

Psoriasis is an immunological disease affecting as many as 7.5 million Americans, according to the National Institutes of Health (NIH). Plaque psoriasis, the most common type of psoriasis, is characterized by the formation of lesions, or inflamed patches of skin. The severity of psoriasis can range from a small number of lesions to more severe cases involving moderate to large areas of skin. Psoriasis occurs nearly equally in men and women and can develop at any age, commonly appearing between ages 15 and 35. Approximately 10 to 30 percent of people with psoriasis will develop psoriatic arthritis, according to the National Psoriasis Foundation. In psoriatic arthritis, the joints and the soft tissue around them become inflamed and stiff, affecting the fingers and toes and possibly involving the neck, lower back, knees and ankles. In severe cases, psoriatic arthritis can be disabling and cause irreversible damage to joints.

About Lupus

Approximately 350,000 individuals in the United States are affected with lupus, a chronic inflammatory disease that causes the body to attack its own tissues and organs, including the skin, joints, blood and kidneys. Treatments for lupus include anti-inflammatory drugs, antimalarials, corticosteroids and drugs approved for other purposes, such as immunosuppressive agents given to cancer patients undergoing chemotherapy or medicines developed to treat arthritis patients. Lupus occurs about 10 times more frequently in adult females than adult males, and is two to three times more common among African Americans, Hispanics, Asians and Native Americans.

About MedImmune, Inc.

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious disease, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company’s website at http://www.medimmune.com.

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties, in particular, related to the research and development of antibodies targeting interferon-alpha. Such statements reflect management’s current views and are based on certain assumptions about the success of this program. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in MedImmune’s filings with the SEC. MedImmune is developing interferon-alpha-related product candidates for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.

SOURCE MedImmune, Inc.

CONTACT: Media: Kate Barrett, +1-301-398-4320, or Investors: Beatrice Pierre, +1-301-398-4905, both of MedImmune, Inc.

“While we are currently expanding our biologics manufacturing facility in Frederick, MD, which will increase our capacity to produce pandemic vaccine as well as other products in our pipeline, the immediate availability of the existing Human Genome Sciences facility allows us to expedite certain development steps toward expanding our capacity to produce cell culture-based influenza vaccines,” stated Alan Taggart, MedImmune’s vice president of government project management. “This should be particularly useful as we prepare to initiate our clinical trials of cell culture influenza vaccine under our HHS contract commitment.”

MedImmune currently develops, manufactures and markets FluMist(R) (Influenza Virus Vaccine Live, Intranasal), a live, attenuated, needle-free seasonal influenza vaccine. The company is also working with the National Institute of Health’s National Institute of Allergy and Infectious Diseases (NIAID) to apply MedImmune’s proprietary technology to develop pandemic influenza vaccines.

“HGS and MedImmune work together in a number of ways to advance the interests of the biotechnology industry in Maryland and the Greater Washington region, and we are pleased to extend use of this state-of-the-art facility to MedImmune — particularly for such an important national purpose,” said Curran Simpson, HGS senior vice president of operations. “Our priority focus at HGS is to advance our lead products toward commercialization as rapidly as possible. To that end, we have taken a number of steps to strengthen our financial position and reduce net cash burn, including a facilities consolidation program. This lease is one outcome of that effort.”

Currently, all U.S.-approved influenza vaccines are made in chicken eggs; however, using chicken eggs as the production medium limits scalability in manufacturing and increases the potential risk of manufacturing delays or supply shortages. A severe outbreak of avian influenza could kill the flocks that produce the eggs needed for vaccine production. To address these concerns, MedImmune will be applying advanced cell culture-based manufacturing methods to produce influenza vaccines eliminating the need for chicken eggs. The success of this technology will reduce production times and substantially increase MedImmune’s U.S.-based manufacturing capacity to provide influenza vaccine to the U.S. population. After adding the cell culture-based production capability for its influenza vaccine, MedImmune anticipates having the capacity to produce 300 million monovalent bulk doses of a pandemic vaccine annually by 2012.

About FluMist

FluMist is currently indicated for active immunization for the prevention of disease caused by influenza A and B viruses in healthy children and adolescents, 5 to 17 years of age, and healthy adults, 18 to 49 years of age. There are risks associated with all vaccines, including FluMist. As with any vaccine, FluMist does not protect 100 percent of individuals vaccinated and may not protect against viral strains not contained in the vaccine.

Under no circumstances should FluMist be administered as an injection (i.e. parenterally). FluMist is contraindicated in persons with hypersensitivity to any component of the vaccine, including eggs; in children and adolescents receiving aspirin therapy or aspirin-containing therapy; in individuals with a history of Guillain-BarrA(C) syndrome; and in individuals with known or suspected immune deficiency. The safety and efficacy of FluMist have not been established in pregnant women or for patients with chronic underlying medical conditions, including asthma or reactive airways disease; the vaccine should not be administered to these patients.

In randomized, placebo-controlled clinical trials of FluMist in its refrigerated and frozen formulations, the most common solicited adverse events in the indicated population (n=11,604) included runny nose/nasal congestion, sore throat, cough, irritability, headache, chills, vomiting, muscle aches, decreased appetite, abdominal pain, and decreased activity/feeling of tiredness/weakness.

For information for indications and usage, dosage and administration, and safety information, please see the current Prescribing Information at http://www.flumist.com/pdf/prescribinginfo.pdf, visit http://www.flumist.com, or call 1-877-633-4411 for additional information.

About MedImmune, Inc.

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company’s website at http://www.medimmune.com.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer, rheumatoid arthritis and HIV/AIDS. The Company’s primary focus is rapid progress toward the commercialization of its two lead compounds, Albuferon(R) for hepatitis C, and LymphoStat-B(R) for lupus. Phase 3 clinical trials of both compounds are now underway. For more information, visit the HGS web site at http://www.hgsi.com. HGS, Human Genome Sciences, Albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

MedImmune Forward-Looking Statement

This announcement contains, in addition to historical information, certain forward-looking statements that involve risks and uncertainties, in particular, related to the development of potential influenza vaccines using a cell culture base. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in MedImmune’s filings with the U.S. Securities and Exchange Commission. There can be no assurance that such development efforts will succeed, that such vaccines will receive required regulatory clearance or that, even if such regulatory clearance is received, such vaccines will ultimately achieve commercial success. There can be no assurance that even if such a vaccine is commercially available, that it will protect against a particular influenza strain or prevent a pandemic.

 (1) This project has been funded in whole or in part with Federal funds from the Office of Public Health Emergency Preparedness, Office of Research and Development Coordination, under Contract No. HHS0100200600010C. 

SOURCE MedImmune, Inc.

media
Jamie Lacey
1-301-398-4035
or
investors
Beatrice Pierre
1-301-398-4905
both of MedImmune, Inc.
or
media
Jerry Parrott
1-301-315-2777
or
investors
Kate de Santis
1-301-251-6003
both of Human Genome Sciences
http://www.medimmune.com

“The addition of this novel target to MedImmune’s inflammatory disease pipeline underscores our commitment to developing innovative therapies for the treatment of unmet medical needs, such as systemic lupus erythematosus (SLE or lupus), Sjogrens syndrome and rheumatoid arthritis,” said Anthony J. Coyle, Ph.D., MedImmune senior director, research, and head, inflammation biology. “As we work to develop the anti-ICOS MAb as a potential treatment for such immune system disorders, we also hope to continue to collect scientific knowledge related to the role of signaling pathways in regulating immune response outcomes.”

Under the terms of the agreement, JT will receive an undisclosed upfront payment, milestone payments and royalties on any future marketed products. JT retains exclusive development and marketing rights for the current lead antibody in Japan. MedImmune has exclusive development and marketing rights to this antibody for the rest of world and certain rights worldwide for other antibodies developed as a result of the agreement.

About Anti-ICOS MAbs

Preclinical study results indicate that ICOS is only expressed on a subset of T cells and is essential for T-cell dependent B-cell activation. In addition, ICOS is required for IL-17 secretion from activated T cells. IL-17 is a T-cell derived cytokine that is implicated in the development of various inflammatory diseases, including rheumatoid arthritis. In preclinical studies, ICOS-inhibition with MAbs was shown to be effective in models of rheumatoid arthritis, asthma, multiple sclerosis and lupus.

About Japan Tobacco

Japan Tobacco Inc. is the world’s third largest international manufacturer of tobacco products. Since its privatization in 1985, JT has actively diversified its operations into pharmaceuticals and foods. JT entered into the pharmaceutical business in 1987 and established the Central Pharmaceutical Research Institute in 1993. JT is currently engaged in the research and development of new drugs in various areas such as glucose and lipid metabolism, anti-virus, immune disorders and inflammation, and bone metabolism. The company’s net sales were 4.637 trillion yen in the fiscal year that ended March 31, 2006.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company’s website at http://www.medimmune.com.

This announcement contains, in addition to historical information, certain “forward-looking statements” regarding the development of inflammatory disease product candidates by MedImmune, Inc. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change current expectations and could cause actual outcomes and results to differ materially from current expectations. In addition, MedImmune can provide no assurance that these products will be commercially successful. In addition to risks and uncertainties disclosed in MedImmune’s filings with the U.S. Securities and Exchange Commission, no assurance exists that development efforts for these products will succeed, that these products will receive required regulatory approval or that, even if regulatory approval is received, they will be commercially successful. MedImmune undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise except as may be required by applicable law or regulation.

SOURCE:
MedImmune, Inc.

CONTACT:
Media -
Jamie Lacey
+1-301-398-4035

Investors -
Peter Vozzo
+1-301-398-4358
both of MedImmune, Inc.

– 10th Consecutive Year for MedImmune on the Fast 50 List -

GAITHERSBURG, Md., Sept. 29 /PRNewswire-FirstCall/ — MedImmune, Inc. has been named to Deloitte’s Maryland Technology Fast 50 program for the tenth consecutive year. The Technology Fast 50 is a ranking of the fastest growing technology companies in the area by Deloitte & Touche LLP. Rankings are based on the percentage growth over five years from 2001-2005.

“We are pleased to be recognized again by Deloitte & Touche as one of the area’s fastest growing technology companies,” said Lota S. Zoth, MedImmune’s chief financial officer. “Our continued inclusion in the Fast 50 program reflects the fact that MedImmune has doubled its revenues over the last five years, reaching $1.2 billion in 2005. Our goal is to continue to grow our business by aggressively investing in research and development activities. Toward this end, during 2005 we completed several late-stage clinical trials, started clinical testing on three new promising compounds, and expanded our product portfolio with almost a dozen new targets.

“MedImmune’s fast-paced growth continues in 2006,” Zoth said. “We submitted data to the FDA to expand our label indication for FluMist(R) (Influenza Virus Vaccine Live, Intranasal); we entered into an agreement with Infinity Pharmaceuticals to develop cancer drugs focused on two of the most attractive targeted therapy opportunities in cancer research today; we completed a Phase 3 study with our next-generation monoclonal antibody to prevent respiratory syncytial virus (RSV); and we initiated clinical testing with several new compounds, including those targeting lupus, RSV, parainfluenza virus type 3, B-cell lymphomas, and avian influenza viruses. We also received a $170-million contract from the U.S. Health and Human Services Department to expedite development of cell culture-based production of our flu vaccine, and earlier this month we broke ground on the first phase of a planned 700,000 square-foot expansion of our cell culture manufacturing facility in Frederick, Maryland.”

“To rank on Deloitte’s Technology Fast 50, companies must have phenomenal revenue growth over five years,” said Andrew Harrs, Deloitte’s Southeast regional managing partner for the Technology, Media and Telecommunications Industry Practice. “MedImmune has proven to be one of the fast-growth success stories in Maryland, and we applaud their dedication to making their vision a reality.”

The Maryland Technology Fast 50 program is presented by Deloitte and sponsored by Wilmer Cutler Pickering Hale and Dorr, NASDAQ and UK Trade & Investment. Media sponsors include PR Newswire and Washington SmartCEO magazine.

To qualify for the Technology Fast 50, companies must have had operating revenues of at least $50,000 in 2001 and $5,000,000 in 2005, be headquartered in North America, and be a company that owns proprietary technology that contributes to a significant portion of the company’s operating revenues; or devotes a significant proportion of revenues to the research and development of technology.

Winners of the 16 regional Technology Fast 50 programs in the United States and Canada are automatically entered in Deloitte’s Technology Fast 500 program, which ranks North America’s top 500 fastest growing technology, media, telecommunications and life sciences companies. For more information on the Technology Fast 50 or Technology Fast 500 programs, visit http://www.fast500.com.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With more than 2,400 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company’s website at http://www.medimmune.com.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms and their respective subsidiaries and affiliates. As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other’s acts or omissions. Each of the member firms is a separate and independent legal entity operating under the names “Deloitte,” “Deloitte & Touche,” “Deloitte Touche Tohmatsu” or other related names. Services are provided by the member firms or their subsidiaries or affiliates and not by the Deloitte Touche Tohmatsu Verein.

Deloitte & Touche USA LLP is the U.S. member firm of Deloitte Touche Tohmatsu. In the U.S., services are provided by the subsidiaries of Deloitte & Touche USA LLP (Deloitte & Touche LLP, Deloitte Consulting LLP, Deloitte Financial Advisory Services LLP, Deloitte Tax LLP and their subsidiaries), and not by Deloitte & Touche USA LLP.

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in the company’s filings with the U.S. Securities and Exchange Commission. The company is developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.

SOURCE MedImmune, Inc.

CONTACT: Media: Kate Barrett, +1-301-398-4320, Investors: Peter Vozzo, +1-301-398-4358, both of MedImmune, Inc.

Recent highlights
• Phase 3 study to begin in 2006 with Abegrin(TM) in metastatic melanoma patients
• Preclinical and clinical data with Abegrin presented at the annual meeting of the American Association for Cancer Research and the Canadian Melanoma Conference
• Dosing initiated in Phase 1 study with MEDI-545 in lupus patients
• Human papillomavirus vaccine licensed to GlaxoSmithKline (Cervarix(R)) submitted for marketing approval to European regulatory agency

GAITHERSBURG, Md., April 20 /PRNewswire-FirstCall/ — MedImmune, Inc. (Nasdaq: MEDI) announced today that total revenues for the 2006 first quarter were $498 million compared to $510 million in the 2005 first quarter.

“While we continue to make excellent progress toward achieving our long-term objectives of $2 billion in revenues and $2.00 in earnings per share in 2009, before share-based compensation expense, our recent sales results have been disappointing,” stated David M. Mott, president and chief executive officer. “As described on our year-end earnings call in February, several factors impacted U.S. sales of Synagis(R) (palivizumab) at the outset of the 2005-2006 respiratory syncytial virus (RSV) season from which we had hoped to be able to recover as the season progressed. Unfortunately, the effect of these factors — including changes in payer guidelines, disruptions in our distribution network, and the one-time effects of Hurricanes Rita and Katrina — have taken a more significant toll on seasonal sales of Synagis than previously expected. We have made a number of changes to our marketing and sales organization and our Synagis distribution network and are in the process of completing a significant expansion of our sales team in connection with the previously announced buyout of Abbott’s U.S. co-promotion rights for Synagis following the 2005-2006 RSV season. Following a difficult 2005-2006 RSV season, we expect worldwide reported Synagis sales to resume a pattern of high single-digit growth rates in the second half of this year.”

The company’s net earnings for the 2006 first quarter were $47 million, or $0.18 per diluted share, including share-based compensation expense and as calculated in accordance with generally accepted accounting principles (GAAP). Excluding share-based compensation expense, net earnings were $59 million, or $0.23 per diluted share, compared to $114 million, or $0.45 per diluted share, reported in the 2005 first quarter. The 2006 first quarter results reflect the impact of the company’s increased investment in its long-term business plan.

Mott continued, “With just under a third of product sales being reinvested in research and development, we are making tremendous progress toward building the long-term value of our business. In 2006, we expect to have two product candidates in registration, approximately 15 additional product candidates in clinical testing, including two in Phase 3 trials and at least three Investigational New Drug applications. We have one of the most robust pipelines in the biotechnology industry. We expect this pipeline will deliver meaningful returns on our current investment in the 2007-to-2009 timeframe.”

Product Sales

Total product sales for the 2006 first quarter were $492 million compared to $509 million in the 2005 first quarter. Worldwide sales of Synagis were $463 million in the 2006 first quarter compared to $472 million in the first quarter last year. Sales of Synagis to our international distributor, Abbott International (AI), were $29 million in the 2006 first quarter compared to $32 million in the 2005 first quarter, reflecting the timing of orders from AI. In the U.S., sales of Synagis were $434 million in the 2006 quarter, compared to $440 million in the first quarter of 2005. The factors that contributed to a slower than expected start to the 2005-2006 RSV season in the U.S., as stated above, continued to affect U.S. sales in the 2006 first quarter.

Worldwide sales of Ethyol(R) (amifostine) were $20 million in the 2006 first quarter compared to $23 million in the first quarter last year. The company believes that the decrease in sales is primarily due to the continued challenge presented by alternative therapies in the marketplace.

Margin and Operating Expense Analysis

On January 1, 2006, MedImmune adopted the new accounting standard (Statement of Financial Accounting Standards No. 123R) that requires the company to recognize expense associated with share-based compensation arrangements, including stock options. This expense is reflected in inventory, cost of goods sold, research and development (R&D) and selling, general and administrative expenses (SG&A). To aid investors in understanding the underlying components of our business, MedImmune has separately identified the share-based compensation expense in the following discussion.

Gross margins on product sales were 75 percent in the 2006 first quarter and 76 percent in the 2005 first quarter. The impact of seasonally low sales volumes for FluMist continues to exert downward pressure on overall gross margins. Excluding the impact of FluMist, first-quarter gross margins were 77 percent in both the 2006 and 2005 periods. Share-based compensation expense did not significantly impact gross margins in the 2006 first quarter.

Research and development expenses were $88 million in the 2006 first quarter. Excluding the impact of share-based compensation expense, R&D expenses were $84 million in the 2006 first quarter compared to $69 million in the 2005 first quarter. This increase in R&D expenses is primarily due to a higher level of activity from new and ongoing collaboration agreements, preclinical research and process development activities, and clinical trials for product candidates, including Numax(TM).

Selling, general and administrative expenses were $212 million in the 2006 first quarter. Excluding the impact of share-based compensation expense, SG&A expenses were $206 million, or 42 percent of product sales, in the 2006 first quarter, up from $158 million, or 31 percent of product sales, in the 2005 first quarter. SG&A expense in the first quarter of 2006 included amortization expense of $43 million, or 9 percent of product sales, related to the reacquisition of domestic promotion rights to Synagis, and $90 million, or 18 percent of product sales, of co-promotion expense. Recurring SG&A expenses of $73 million or 15 percent of product sales, included in the annualized impact of 2005 additions to the pediatric sales organization.

The effective tax rate for the 2006 first quarter was 44 percent. Excluding the impact of share-based compensation expense, the effective tax rate was 37 percent compared to 35 percent reported in the 2005 first quarter, reflecting the current absence of certain federal tax credits associated with research and development activities and increased state taxes.

Share-based compensation expense before taxes approximated $10 million in the 2006 first quarter, and was allocated to inventory, cost of goods sold, R&D expense and SG&A expense. The after-tax impact of share-based compensation expense was approximately $12 million. The total number of stock options granted in the 2006 first quarter was 3.4 million, compared to 4.0 million in the 2005 first quarter.

Other Results

Cash and marketable securities at March 31, 2006 were $1.6 billion as compared to $1.5 billion at December 31, 2005. The increase is primarily due to cash generated by operations during the quarter offset by continued investment in property, plant and equipment.

2006 Guidance

As a convenience to investors, MedImmune is providing an update to its previously issued guidance for 2006. MedImmune now expects that total revenues for 2006 will grow about 4 percent to approximately $1.3 billion. Following lower than expected sales of Synagis in the first half of 2006, MedImmune believes that worldwide sales of Synagis will resume their pattern of growth in the second half of the year such that worldwide sales of Synagis for the full calendar year will be about even with 2005.

In the aggregate, MedImmune now expects the 2006 impact of share-based compensation expense to be approximately $37 million, or $0.11 per diluted share, and to be allocated in roughly the same proportion as in the first quarter. The following guidance is provided excluding the impact of share-based compensation expense.

• Gross margins are expected to be about 73 percent of product sales for the full-year 2006.
• R&D expense in 2006 is expected to be approximately $375 million, or about 31 percent of product sales.
• SG&A as a percentage of product sales is expected to be about 40 percent. SG&A is expected to include approximately seven percentage points attributable to amortization of the repurchase of Synagis co- promotion rights from Abbott and approximately eight percentage points attributable to co-promotion expense. Co-promotion expenses are expected to cease mid-year 2006, and will be only partially offset by approximately $25 million in annualized selling expense due to the addition of 125 new sales representatives.
• The company’s effective tax rate is expected to be approximately 37 percent.

MedImmune expects 2006 earnings per diluted share will range from $0.30 to $0.35 before share-based compensation expense, and $0.19 to $0.24, including share-based compensation.

DISCLOSURE NOTICE AND FORWARD LOOKING STATEMENTS

This announcement contains historical financial information as of and for the three-month periods ended March 31, 2006 and March 31, 2005 that is unaudited (except for the balance sheet information as of December 31, 2005), and MedImmune assumes no obligation to update this information based on new information or future performance except as may be specifically required by applicable law or regulation.

This announcement also contains forward-looking statements regarding MedImmune’s future financial performance and business prospects. Those statements involve substantial risks and uncertainties and are present in the section captioned “2006 Guidance,” as well as other sections containing statements with words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “project” or other terms of similar meaning. Those statements reflect management’s current beliefs and are based on numerous assumptions, which MedImmune cannot control and which may not develop as MedImmune expects for reasons set forth in MedImmune’s Annual Report on Form 10-K for the year ended December 31, 2005, its subsequent quarterly reports on Form 10-Q, its current reports on Form 8-K filed for events occurring in 2006 and other public disclosures and filings with the U.S. Securities and Exchange Commission. Consequently, actual results may differ materially from those projected in the forward-looking statements.

MedImmune is also developing several products for potential future marketing and the overall success of these development efforts is important for the company’s long-term prospects. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance is received, such products will ultimately achieve commercial success.

This press release, including the reconciliation of certain historical data presented in this release to their most comparable GAAP measures, can be found on MedImmune’s website at http://www.medimmune.com in the box marked “News” or with the archived press releases on the Investor Summary page.

Conference Call & Webcast

MedImmune is offering a live webcast of a discussion by MedImmune management of its earnings and other business results on Thursday, April 20, 2006 at 8:00 a.m. eastern time. The live webcast may be accessed in the investor section of MedImmune’s website, http://www.medimmune.com. A replay of the webcast will also be available via the MedImmune website until April 27, 2006. An audio replay of the webcast will be available beginning at 10:00 a.m. eastern time on April 20, 2006 and ending at midnight April 27, 2006 by calling (888) 286-8010. The passcode for the audio replay is 84848704.

About MedImmune, Inc.

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious disease, cancer and inflammatory diseases. With more than 2,200 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company’s website at http://www.medimmune.com.

 Cervarix(R) is a registered trademark of GlaxoSmithKline. MedImmune, Inc. Consolidated Statements of Operations (in millions, except per share data) (unaudited) Three Months Ended March 31, 2006 2005 Revenues: Product sales $491.6 $508.7 Other revenue 6.4 1.1 Total revenues 498.0 509.8 Costs and expenses: Cost of sales 123.1 119.8 Research and development 87.9 69.3 Selling, general and administrative (1) 211.9 157.5 Other operating expenses 2.7 2.6 Total expenses 425.6 349.2 Operating income 72.4 160.6 Interest income, net 13.0 14.7 Gain (loss) on investment activities (0.8) 0.3 Earnings before income taxes 84.6 175.6 Provision for income taxes 37.6 61.5 Net earnings $ 47.0 $114.1 Basic earnings per share $ 0.19 $ 0.46 Shares used in computing basic earnings per share 247.9 248.1 Diluted earnings per share (2) $ 0.18 $ 0.45 Shares used in computing diluted earnings per share (2) 260.0 257.2 (1) In August 2005, the company acquired full promotion rights in the U.S. for Synagis, effective July 1, 2006. In connection with this transaction, the company recorded an intangible asset of $360.4 million which represents the fair value of the exclusive promotion rights, determined as the aggregate value of the probable additional payments to be made as a result of the amended terms of the agreement in excess of the value of the co-promotion services to be rendered, as determined under the previous agreement. Amortization expense of $43.1 million was recognized during the first quarter of 2006, and is included in selling, general & administrative expense in the consolidated statements of operations. (2) In accordance with EITF No. 04-8, "The Effect of Contingently Convertible Debt on Diluted Earnings per Share," which became effective during 2004, the company's 1% Convertible Senior Notes, which represent 7.3 million potential shares of common stock, are now included in diluted earnings per share using the if-converted method, regardless of whether the market price trigger has been met, unless the effect is anti-dilutive. Earnings used in computing diluted earnings per share, after assumed conversion of convertible notes, was $47.5 million and $114.7 million for the three months ended March 31, 2006 and 2005, respectively. MedImmune, Inc. Reconciliation of GAAP Results to Adjusted Results (in millions, except per share data) Presented in the following table is a reconciliation of reported net earnings under accounting principles generally accepted in the U.S. (GAAP) to net earnings excluding the impact of employee stock-based compensation expense. Three Months Ended March 31, 2006 2005 (Unaudited) Item: Net earnings, as reported (1) $ 47.0 $114.1 Share-based compensation expense (2) Cost of sales 0.4 - Research and development 3.7 - Selling, general and administrative 5.6 - 9.7 - Income taxes - deductible portion (3) (1.7) - 8.0 - Income taxes - nondeductible portion (3) 4.1 - Net earnings, as adjusted $ 59.1 $114.1 Basic earnings per share, as reported 0.19 0.46 Diluted earnings per share, as reported 0.18 0.45 Basic earnings per share, as adjusted 0.24 0.46 Diluted earnings per share, as adjusted 0.23 0.45 Shares used to compute earnings per share: Basic, as reported 247.9 248.1 Diluted, as reported 260.0 257.2 Basic, as adjusted 247.9 248.1 Diluted, as adjusted 259.7 257.2 (1) Prepared in accordance with accounting principles generally accepted in the United States (GAAP). (2) Represents the addback of the noncash employee share-based compensation expense. (3) Share-based compensation expense is comprised of incentive stock options, non-qualified stock options and the discount on stock purchased by employees. If incentive stock options are exercised and sold or stock purchased by employees through the employee stock purchase plan is sold within one year, becoming non-qualifying dispositions, the company will be allowed to recognize tax deductions at that time. Until that time, the company must assume that no tax deduction is allowed. Separately identified in this table for the quarter is the tax deduction allowed for non-qualified stock option expense and the nondeductible portion attributable to incentive stock options and the discounted employee stock purchase plan. MedImmune, Inc. Condensed Consolidated Balance Sheets (1) (in millions)  March 31, December 31, 2006 2005 (unaudited) (audited) Assets: Cash and marketable securities $1,637.7 $1,471.9 Trade and contract receivables, net 283.9 284.3 Inventory, net 70.5 69.4 Deferred taxes, net 162.1 186.6 Property and equipment, net 399.4 381.4 Intangible assets, net (2) 278.2 323.5 Other assets 59.1 62.9 $2,890.9 $2,780.0 Liabilities and shareholders' equity: Accounts payable $ 36.8 $ 37.0 Accrued expenses 403.9 335.1 Other liabilities (2) 276.2 331.2 Debt 505.9 506.2 Shareholders' equity 1,668.1 1,570.5 $2,890.9 $2,780.0 Common shares outstanding 248.7 247.0 (1) Certain prior period amounts have been reclassified to conform to current presentation. (2) In August 2005, the company acquired full promotion rights in the U.S. for Synagis(R), effective July 1, 2006. In connection with this transaction, the company recorded an intangible asset of $360.4 million which represents the fair value of the exclusive promotion rights, determined as the aggregate value of the probable additional payments to be made as a result of the amended terms of the agreement in excess of the value of the co-promotion services to be rendered, as determined under the previous agreement. In addition, certain of the additional payments under the agreement totaling $252.5 million that the company deems probable have been aggregated and recorded as liabilities in the consolidated balance sheet. 

SOURCE MedImmune, Inc. CONTACT: Investors – Peter Vozzo, +1-301-398-4358, or Media – Jamie Lacey, +1-301-398-4035, both of MedImmune, Inc.

GAITHERSBURG, Md., April 13 /PRNewswire-FirstCall/ — MedImmune, Inc. (Nasdaq: MEDI) announced today that it has begun dosing lupus patients in a Phase 1 clinical trial to evaluate the safety and tolerability of MEDI-545, its monoclonal antibody (MAb) targeting interferon-alpha. The MAb is being developed for the potential treatment of patients with systemic lupus erythematosus (SLE or lupus).

“Moving forward with our clinical program for MEDI-545 in lupus patients is an exciting next step in our plan to develop new treatments for patients suffering from inflammatory diseases,” said Stanley Pillemer, M.D., MedImmune’s senior director, clinical development, inflammatory disease. “With this Phase 1 program, we look to further increase our knowledge about the role of interferons in lupus disease activity, with the hope of developing a new medical option for patients suffering from this debilitating disease.”

MedImmune’s Lupus Interferon Skin Activity (LISA) study is a Phase 1, randomized, double-blind, placebo-controlled, dose-escalation study involving a single intravenous dose of the anti-interferon-alpha antibody in patients who have mild SLE with lupus rash or skin lesions. Forty-five individuals will be enrolled at approximately 20 centers in North America.

MedImmune’s development of MAbs targeting interferon-alpha stems from a collaboration agreement entered into with Medarex, Inc. in 2004 to focus on two specific antibodies, one of which was MDX-1103 (now known as MEDI-545). Under the terms of the agreement, MedImmune is responsible for all ongoing clinical development activities.

“We are pleased that the development of this product candidate continues to advance toward potentially helping patients fight the effects of a serious condition,” said Donald L. Drakeman, president and CEO of Medarex.

About MEDI-545 (Anti-IFN-alpha MAb)

MEDI-545 is a fully human monoclonal antibody (MAb) targeting interferon- alpha. Published preclinical data indicate that levels of interferon-alpha are elevated in many patients with active systemic lupus erythematosus (SLE or lupus) and other autoimmune disorders, and may be associated with disease activity. Preclinical data from animal models suggest that MEDI-545 may suppress the abnormal immune activity associated with lupus by binding to multiple interferon-alpha subtypes seen in the serum of lupus patients.

About Lupus

Approximately 350,000 individuals in the United States are affected with SLE, a chronic inflammatory disease that causes the body to attack its own tissues and organs, including the skin, joints, blood and kidneys. Treatments for lupus include anti-inflammatory drugs, antimalarials, corticosteroids and drugs approved for other purposes, such as immunosuppressive agents given to cancer patients undergoing chemotherapy or medicines developed to treat arthritis patients. Lupus occurs about 10 times more frequently in adult females than adult males, and is two to three times more common among African Americans, Hispanics, Asians and Native Americans.

About MedImmune, Inc.

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With more than 2,200 employees worldwide, MedImmune is headquartered in Gaithersburg, Maryland. For more information, visit the company’s website at http://www.medimmune.com.

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties, in particular, related to the research and development of antibodies targeting interferon-alpha. Such statements reflect management’s current views and are based on certain assumptions about the success of this program. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in MedImmune’s filings with the SEC. MedImmune is developing interferon-alpha-related product candidates for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.

This press release can be found on MedImmune’s website at http://www.medimmune.com in the box marked “News” or with the archived press releases on the Investor Summary page.

SOURCE MedImmune, Inc.

CONTACT: Investors: Peter Vozzo, +1-301-398-4358; Media: Kate Barrett, +1-301-398-4320 or Jamie Lacey, +1-301-398-4035, all of MedImmune, Inc.